LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its financial results for the fourth quarter and fiscal year 2024, ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced a strategic loan and security agreement with Hercules Capital, Inc. ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

SAVARA ($SVRA) is expected to release its quarterly earnings data on Wednesday, April 2nd after market close, per Finnhub. Analysts are expecting revenue of $0 and ...

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Savara (SVRA – Research Report) yesterday and set a price target of $3.00. The ...

Swiss National Bank lessened its position in shares of Savara Inc (NASDAQ:SVRA – Free Report) by 6.7% during the fourth ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Savara Inc (NASDAQ:SVRA – Free Report) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Savara in a note issued to investors on Friday ...

As of December 31, 2024, the company had cash, cash equivalents and short-term investments of $196.3M. “Completing submission of the BLA is an ...

Savara's net loss for the fourth quarter of 2024 was $29.0 million, or $(0.13) per share, compared with a net loss of $16.1 million, or $(0.09) per share, for the fourth quarter of 2023.

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending ...